Approaches to japanese dose evaluation in global drug development: Factors that generate different dosages between Japan and the United States

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 6, 2011, Pages 836-843

  Nakashima, K ^a   Narukawa, M ^a   Takeuchi, M ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BROMOCRIPTINE; DORIPENEM; ENALAPRIL; ENTACAPONE; ETANERCEPT; INSULIN DETEMIR; INSULIN GLARGINE; IRBESARTAN; IRBETAN; LEVODOPA; LOSARTAN; OLMESARTAN; ROPINIROLE; ROSUVASTATIN; TELITHROMYCIN; TOPIRAMATE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; EPILEPSY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; JAPAN; MAXIMUM PLASMA CONCENTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; STUDY DESIGN; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG DESIGN; HUMANS; JAPAN; PHARMACEUTICAL PREPARATIONS; TIME FACTORS; UNITED STATES;

EID: 81355135357     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.156     Document Type: Article

References (26)

1. Malinowski, H.J., Westelinck, A., Sato, J. & Ong, T. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J. Clin. Pharmacol. 48, 900-908 (2008). (Pubitemid 352009498)
2. Nakashima, K., Narukawa, M., Kanazu, Y. & Takeuchi, M. Differences between Japan and the United States in dosages of drugs recently approved in Japan. J. Clin. Pharmacol. 51, 549-560 (2011).
3. Uyama, Y., Shibata, T., Nagai, N., Hanaoka, H., Toyoshima, S. & Mori, K. Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin. Pharmacol. Ther. 78, 102-113 (2005). (Pubitemid 41112277)
4. International Conference on Harmonisation. Harmonised Tripartite Guideline. Ethnic factors in the acceptability of foreign clinical data. ICH-E5(R1). Current Step 4 version 〈http://www.ich.org/fileadmin/Public- Web-Site/ICH-Products/Guidelines/Efficacy/E5-R1/Step4/E5-R1-Guideline.pdf〉 (1998)
5. Ministry of Health, Labour and Welfare of Japan. Basic principles on global clinical trials 〈http://www.pmda.go.jp/english/service/pdf/ notifications/0928010-e.pdf〉 (28 September 2007).
6. Ichimaru, K., Toyoshima, S. & Uyama, Y. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicityrelated drug response factors. Clin. Pharmacol. Ther. 87, 362-366 (2010).
7. Pharmaceutical and Medical Devices Agency, Japan. Adenosine. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200500014/30077600-2170 0AMY00166-Q100-2.pdf〉 〈http://www.info.pmda.go.jp/shinyaku/P200500 014/30077600-21700AMY00166-Q101-2.pdf〉 [in Japanese] (11 April 2005).
8. Pharmaceutical and Medical Devices Agency, Japan. Olmesartan medoxomil. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200400005/3001560 0-21600AMZ00030-A100.1.pdf〉 [in Japanese] (29 January 2004).
9. Pharmaceutical and Medical Devices Agency, Japan. Irbesartan. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200800021/34001800-220 00AMX01600-A100-1.pdf〉 〈http://www.info.pmda.go.jp/shinyaku/P2008 00021/34001800-22000AMX01600-A101-1.pdf〉 〈http://www.info.pmda. go.jp/shinyaku/P200800021/331014000-22000AMX01600-A110-1.pdf〉 [in Japanese] (16 April 2008).
10. Pharmaceutical and Medical Devices Agency, Japan. Entacapone. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200700012/300242000-21900AMX00 048000-A100-1.pdf〉 [in Japanese] (26 January 2007).
11. Pharmaceutical and Medical Devices Agency, Japan. Rosuvastatin calcium. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200500004/67022700- 21700AMY 00008-A100-1.pdf〉 〈http://www.info.pmda.go.jp/shinyaku/ P200500004/6702270 0-21700AMY00008-A101-1.pdf〉 〈http://www.info.pmda. go.jp/shinyaku/P20050 0004/67022700-21700AMY00008-A102-1.pdf〉 [in Japanese] (19 January 2005).
12. Pharmaceutical and Medical Devices Agency, Japan. Telithromycin. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200300022/78006900-21500A MY00130-Q100-1.pdf〉 〈http://www.info.pmda.go.jp/shinyaku/P200300022/7 8006900-21500AMY00130-Q101-1.pdf〉 [in Japanese] (16 October 2003).
13. Pharmaceutical and Medical Devices Agency, Japan. Insuline glargine. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200300024/78006900- 21500A MY00131-Q100-1.pdf〉 [in Japanese] (16 October 2003).
14. Pharmaceutical and Medical Devices Agency, Japan. Insuline detemir. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200700051/620023000- 21900 AMX01761000-A100-2.pdf〉 [in Japanese] (19 October 2007).
15. Pharmaceutical and Medical Devices Agency, Japan. Topiramate. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200700033/23012400-2190 0AMY00038-A100-1.pdf〉 [in Japanese] (31 July 2007).
16. Pharmaceutical and Medical Devices Agency, Japan. Etanercept. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200500002/53039601-21700AM Y00005-A100-2.pdf〉 〈http://www.info.pmda.go.jp/shinyaku/P200500002/ 53039601-21700AMY00005-A101-1.pdf〉 〈http://www.info.pmda.go.jp/ shinyaku/P200500002/53039601-21700AMY00005-A102-1.pdf〉 〈http://www. info.pmda.go.jp/shinyaku/P200500002/53039600-21700AMY0000 5-A103-1.pdf〉 [in Japanese] (19 January 2005).
17. Pharmaceutical and Medical Devices Agency, Japan. New 5 year goals for FY2007-2011 〈http://www.pmda.go.jp/guide/hyougikai/19/h190608gijishidai/ file/shiryo3-1.pdf〉 [in Japanese] (2007).
18. Ichimaru, K., Toyoshima, S. & Uyama, Y. PMDA's challenge to accelerate clinical development and review of new drugs in Japan. Clin. Pharmacol. Ther. 88, 454-457 (2010).
19. Pharmaceutical and Medical Devices Agency, Japan. Ropinirole hydrochloride. Review report 〈http://www.info.pmda.go.jp/shinyaku/P2 00600042/340278000-21800AMY10123-Q100-1.pdf〉 〈http://www.info. pmda.go.jp/shinyaku/P200600042/340278000-21800AMY10123-Q101-1. pdf〉 〈http://www.info.pmda.go.jp/shinyaku/P200600042/340278000-218 00AMY10123-Q102-1.pdf〉 〈http://www.info.pmda.go.jp/shinyaku/P2006 00042/340278000-21800AMY10123-Q103-1.pdf〉 〈http://www.info.pmda. go.jp/shinyaku/P200600042/340278000-21800AMY10123-Q104-1.pdf〉 [in Japanese] (20 October 2006).
20. Pharmaceutical and Medical Devices Agency, Japan. Doripenem. Review report 〈http://www.info.pmda.go.jp/shinyaku/P200500018/34001800-2170 0AMZ00695-A100-1.pdf〉 [in Japanese] (25 July 2005).
21. Kudrin, A. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia. J. Clin. Pharmacol. 49, 268-280 (2009).
22. C ross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C. & Peck, C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 11, 439-446 (2002). (Pubitemid 35214702)
23. Heerdink, E.R., Urquhart, J. & Leufkens, H.G. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol. Drug Saf. 11, 447-453 (2002). (Pubitemid 35214703)
24. Boudier, S. A drug is not a drug is not a drug: a commentary. Pharmacoepidemiol. Drug Saf. 11, 437-438 (2002).
25. Honig, P. Benefit and risk assessment in drug development and utilization: a role for clinical pharmacology. Clin. Pharmacol. Ther. 82, 109-112 (2007). (Pubitemid 47075348)
26. Peck, C.C. & Cross, J.T. "Getting the dose right": facts, a blueprint, and encouragements. Clin. Pharmacol. Ther. 82, 12-14 (2007).